Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB)

被引：3
|
作者：
Piratvisuth, T.
Lau, G. K. K.
Marcellin, P.
Chow, W. C.
Cooksley, G.
Fried, M. W.
Paik, S. W.
Liaw, Y. F.
Popescu, M.
Button, P.
机构：
[1] Prince Songkla Univ, Dept Internal Med, Songklanagarind Hosp, Hat Yai, Thailand
[2] Univ Hong Kong, Queen Marys Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Hop Beaujon, Serv Hepatol, Clichy, France
[4] Singapore Gen Hosp, Dept Gastroenterol, Singapore 0316, Singapore
[5] Royal Brisbane Hosp, Dept Clin Res, Brisbane, Qld 4029, Australia
[6] Univ N Carolina, Univ N Carolina Liver Program, Chapel Hill, NC USA
[7] Samsung Med Ctr, Dept Gastroenterol, Seoul, South Korea
[8] Chang Gung Mem Hosp, Linkou, Taiwan
来源：
JOURNAL OF HEPATOLOGY | 2006年 / 44卷
关键词：
D O I：
10.1016/S0168-8278(06)80050-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
49
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [41] Sustained HBSAG seroconversion in patients with chronic hepatitis B treated with peginterferon α-2a (40 kDa) (PEGASYS®)
    Hadziyannis, S
    Lau, GKK
    Marcellin, P
    Piratvisuth, T
    Cooksley, G
    Bonino, F
    Chutaputti, A
    Diago, M
    Jin, R
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2005, 42 : 178 - 178
  • [42] Effect of ethnicity, genotype, gender, age and bodyweight on sustained response in a large, randomised study of peginterferon alfa-2A (40KD) (PEGASYS®) +/- lamivudine versus lamivudine alone for HBEAG-positive chronic hepatitis B
    Chow, WC
    Manns, M
    Paik, SW
    Berg, T
    Piratvisuth, T
    Chang, WY
    Lau, GK
    Marcellin, P
    Gane, E
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 576A - 576A
  • [43] HBeAg-positiye chronic hepatitis B (CHB) patients with difficult-to-treat disease improved response rates with peginterferon alfa-2a (40KD) (pegasys®) compared with conventional
    Graham, W
    Cooksey, E
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chang, WY
    Zahm, FE
    Pluck, N
    HEPATOLOGY, 2002, 36 (04) : 374A - 374A
  • [44] PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE
    Chan, H. L.
    Ahn, S. H.
    Chang, T. -T.
    Peng, C. -Y.
    Wong, D.
    Coffin, C. S.
    Lim, S. G.
    Chen, P. -J.
    Janssen, H. L.
    Marcellin, P.
    Serfaty, L.
    Zeuzem, S.
    Cohen, D.
    Critelli, L.
    Xu, D.
    Cooney, E.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S48 - S48
  • [45] On-treatment predictors of sustained biochemical and virological response in patients with HBeAg-negative chronic hepatitis B (CHB) treated with peginterferon α-2a (40 kDa) (Pegasys®)
    Farci, P
    Marcellin, P
    Lu, ZM
    Diago, M
    Lai, MY
    Gurel, S
    Kittis, G
    Yurdaydin, C
    Zahm, F
    Bonino, F
    JOURNAL OF HEPATOLOGY, 2005, 42 : 175 - 175
  • [46] Effect of ALT flares on efficacy and safety of peginterferon α-2a (40kDa) (Pegasys®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)
    Piratvisuth, T
    Lu, KX
    Marcellin, P
    Chang, WY
    Berg, T
    Flisiak, R
    Chao, YC
    Paik, SW
    Thongsawat, S
    McCloud, P
    JOURNAL OF HEPATOLOGY, 2005, 42 : 189 - 190
  • [47] Use of on-Treatment HBsAg Level and HBeAg Index Can Early Predict Sustained Virological Response in Chronic Hepatitis B, HBeAg Positive Patients Treated With Peginterferon ALPHA-2A
    Phisalprapa, Pochamana
    Charatchamenwitthaya, Phunchai
    Chainuvati, Siwaporn P.
    Nimanong, Supot
    Pausawasdi, Nonthalee
    Prachayakul, Varaytt
    Pongprasubchai, Supot
    Leelakusolvong, Somchai
    Manatsathit, Satapom
    Kachintorn, Udom
    Tanwandee, Tawesak
    GASTROENTEROLOGY, 2011, 140 (05) : S931 - S931
  • [48] ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB)
    Chan, H. L.
    Ahn, S. H.
    Chang, T. -T.
    Peng, C. -Y.
    Wong, D.
    Coffin, C.
    Lim, S. G.
    Chen, P. -J.
    Janssen, H. L.
    Marcellin, P.
    Serfaty, L.
    Zeuzem, S.
    Hu, W.
    Critelli, L.
    Wind-Rotolo, M.
    Srinivasan, S.
    Lopez-Talavera, J. C.
    Cooney, E.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S300 - S300
  • [49] TREATMENT OF HBEAG-POSITIVE CHB INFECTION WITH PEGINTERFERON ALFA-2A [40KD] PLUS LAMIVUDINE OR ADEFOVIR FOR 96 WEEKS RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION
    Cao, Zhenhuan
    Zhang, Yonghong
    Ma, Lina
    Jin, Yi
    Yu, Haibin
    Zhang, Xiao-dan
    Liu, Yali
    Huang, Yanxiang
    Ma, Bing
    Ren, Shan
    Wang, Lilin
    Chen, Xin-Yue
    Wei, Lai
    HEPATOLOGY, 2010, 52 (04) : 507A - 507A
  • [50] HBeAg INDEX AND HBV DNA REDUCTION CAN PREDICT LONG TERM RESPONSE OF CHRONIC HEPATITIS B, HBeAg POSITIVE PATIENTS TREATED WITH PEGINTERFERON ALPHA-2a: A THREE-YEAR FOLLOW-UP
    Phisalprapa, P.
    Charatcharoenwitthaya, P.
    Chainuwatti, S.
    Chotiyaputta, W.
    Nimanong, S.
    Tanwandee, T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S203 - S204
12345